The estimated Net Worth of Brian K Halak is at least $12.3 Million dollars as of 2 November 2018. Brian Halak owns over 335,000 units of Alimera Sciences stock worth over $105,900 and over the last 17 years he sold ALIM stock worth over $12,173,888. In addition, he makes $0 as Independent Director at Alimera Sciences.
Sign up
Brian Halak ALIM stock SEC Form 4 insiders trading
Brian has made over 7 trades of the Alimera Sciences stock since 2010, according to the Form 4 filled with the SEC. Most recently he sold 335,000 units of ALIM stock worth $4,465,550 on 2 November 2018.
The largest trade he's ever made was buying 3,500,000 units of Alimera Sciences stock on 16 September 2011 worth over $7,000,000. On average, Brian trades about 190,188 units every 69 days since 2007. As of 2 November 2018 he still owns at least 19,150 units of Alimera Sciences stock.
You can see the complete history of Brian Halak stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Brian Halak biography
Dr. Brian K. Halak Ph.D. serves as Independent Director of the Company. Dr. Halak has been a member of the Board since 2004. Dr. Halak joined Domain Associates, L.L.C. in 2001 and has served as a Partner of Domain Associates, L.L.C. since 2006. In this capacity, Dr. Halak has invested in over a dozen companies, three of which he helped create. He served as the CEO of one of the companies he created, WindMIL Therapeutics, from October 2015 through January 2019 and through two rounds of financing. Prior to joining Domain Associates, L.L.C., Dr. Halak served as an analyst at Advanced Technology Ventures from 2000 to 2001. From 1993 to 1995, Dr. Halak served as an analyst at Wilkerson Group. Dr. Halak holds a Doctorate in Immunology from Thomas Jefferson University and a B.S. in Engineering from the University of Pennsylvania. The Board believes that Dr. Halak should continue to serve as a director of the Company, in light of its business and structure, for the following reasons: his valuable contributions to our company in recent years, his experience as CEO of a company and his service on the board of directors of more than 10 emerging companies in the life sciences industry in the past 10 years. These companies include Dicerna Pharmaceuticals, Inc., which completed a public offering on Nasdaq in 2014, Vanda Pharmaceuticals, Inc., a public company listed on Nasdaq, and Esprit Pharma, Inc., a company Allergan acquired in 2007.
How old is Brian Halak?
Brian Halak is 48, he's been the Independent Director of Alimera Sciences since 2004. There are 14 older and 1 younger executives at Alimera Sciences. The oldest executive at Alimera Sciences Inc. is James Largent, 70, who is the Lead Independent Director.
What's Brian Halak's mailing address?
Brian's mailing address filed with the SEC is 6310 TOWN SQUARE, SUITE 400, ALPHARETTA, GA, 30005.
Insiders trading at Alimera Sciences
Over the last 14 years, insiders at Alimera Sciences have traded over $14,704,529 worth of Alimera Sciences stock and bought 8,598,915 units worth $59,337,384 . The most active insiders traders include Capital, Llc Armistice Capi..., Nicole Vitullo, and Jesse I Treu. On average, Alimera Sciences executives and independent directors trade stock every 32 days with the average trade being worth of $468,137. The most recent stock trade was executed by Partners Lpjohnson David Ed... on 14 September 2023, trading 579,000 units of ALIM stock currently worth $1,962,810.
What does Alimera Sciences do?
alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.
What does Alimera Sciences's logo look like?
Complete history of Brian Halak stock trades at Alimera Sciences, Clovis Oncology Inc, Dicerna Pharmaceuticals Inc, Esperion Therapeutics, Evoke Pharma Inc, Tandem Diabetes Care Inc, Vanda Pharmaceuticals Inc, Veracyte Inc, and Zogenix Inc
Alimera Sciences executives and stock owners
Alimera Sciences executives and other stock owners filed with the SEC include:
-
Richard Eiswirth,
President, Chief Executive Officer, Director -
C. Daniel Myers,
Non-Executive Chairman of the Board -
Richard S. Eiswirth Jr.,
Pres, CEO & Director -
David Holland,
Chief Marketing Officer and Senior Vice President Corporate Communications and Managed Markets -
Philip Ashman,
Chief Operating Officer, Senior Vice President - Commercial Operations Europe -
David R. Holland,
Co-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets -
Dr. Philip Ashman,
COO & Sr. VP of Commercial Operations - Europe -
Charles Daniel Myers,
Non-Exec. Chairman & Consultant -
James Largent,
Lead Independent Director -
John Marco,
Investor Relations -
Mary Szela,
Independent Director -
John Snisarenko,
Independent Director -
Peter Pizzo,
Independent Director -
Garheng Kong,
Independent Director -
Brian Halak,
Independent Director -
Samer Kaba,
Chief Medical Officer -
Phil Jones,
Chief Financial Officer -
Dr. David Dyer,
Chief Retina Specialist -
Christopher S. Visick,
VP, Gen. Counsel & Sec. -
J. Philip Jones,
Chief Financial Officer -
Calvin W. Roberts,
Director -
Glen Bradley,
Director -
James E Deerfield Mgmt L.P....,
-
Mark J Brooks,
Director -
Kenneth Green,
SVP & Chief Scientific Officer -
L.P.Mitchell Kateo'driscoll...,
-
Alto Investors Lp Palo,
-
Russell Skibsted,
Chief Financial Officer & SVP -
Capital, Llc Armistice Capi...,
-
Patrick Lee,
10% owner -
Management Viii, L.L.C.Sofi...,
-
Partners Vi, L.P.Blair Jame...,
-
Vi Associates, L.P.Blair Ja...,
-
Jesse I Treu,
10% owner -
Venture Management Co Iv Ll...,
-
Philip R Tracy,
Director -
Susan Caballa,
SEE REMARKS -
Kathleen K Schoemaker,
10% owner -
Partners Vi, L.P. Domain,
10% owner -
James C Blair,
10% owner -
Nicole Vitullo,
10% owner -
Anders D Hove,
Director -
Bryce Youngren,
Director -
Brian H Dovey,
10% owner -
Vi Associates, L.P. Dp,
10% owner -
Associates Iv L P Venrock M...,
-
Associates Vi, Llc Mumma Mi...,
-
Associates Vii, Llc Mumma M...,
-
Associates V, Llc Mumma Mit...,
-
L.P.Bock Louis Cmitchell Ka...,
-
Adam Morgan,
Director -
Stanley Morgan,
10% owner -
Todd Michael Wood,
President of U.S. Operations -
Roger Sawhney,
Director -
Adam Velan Capital Investme...,
-
Partners Lpjohnson David Ed...,
-
Jason M. Werner,
Chief Operating Officer -
Erin Parsons,
-
Michael Kaseta,
-
Ross D De Mont,
-
Margaret Pax,
-
Elliot Maltz,
Chief Financial Officer